Calidad de vida en glioblastoma después de la introducción de temozolomida: una revisión sistemática
DOI:
https://doi.org/10.33448/rsd-v11i15.37205Palabras clave:
Calidad de Vida, Glioblastoma, Temozolomida.Resumen
Introducción: Los gliomas son tumores primarios del sistema nervioso central con un patrón agresivo de progresión con mal pronóstico en términos de supervivencia y calidad de vida. El tratamiento estándar actual consiste en cirugía con escisión máxima asociada a radioterapia y quimioterapia, en su mayoría basada en el uso de temozolomida. Desde su introducción, la calidad de vida de los pacientes que se someten a esta terapia no ha sido objeto de una evaluación amplia. Objetivo: verificar la calidad de vida de los pacientes con glioblastoma después de la introducción de temozolomida en los protocolos terapéuticos. Métodos: Se realizó una revisión sistemática de la literatura guiada por el protocolo PICO y PRISMA; Se consultaron las bases de datos PubMed, Medline y Lilacs. Resultados: Inicialmente se encontraron 77 estudios, luego de criterios de selección se analizaron 35 artículos. No se encontraron cambios estadísticamente significativos en la calidad de vida general en los estudios que analizaron la terapia con temozolomida versus diferentes terapias de control. Conclusión: La asociación de temozolomida con cirugía y radioterapia resultó ser neutra, sin impactos negativos o positivos significativos en la calidad de vida de los pacientes con glioblastoma.
Referencias
Arakawa, Y. et al. (2021). A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 ( AgedGlio -PIII), BMC Cancer, 21 (1), 1-8.
Armstrong, T. S. et al. (2013). Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma, Journal of Clinical Oncology, 31 (32), 4076-4084.
Baba, M. A., Adali, N. (2021). Neurocognitive state and quality of life of patients with glioblastoma in Mediterranean countries: a systematic review. Annals of Palliative Medicine, 10 (11), 11980-11993.
Badruddoja, M. A. et al. (2017). Phase II study of bi-weekly temozolomide plus bevacizumab for adult patients with recurrent glioblastoma, Cancer Chemotherapy and Pharmacology, 80 (4), 715-721.
Brada, M. et al. (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse, Annals of Oncology, 12 (2), 259-266.
Brada, M. et al. (2005). Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide, Annals of Oncology, 16 (6), 942-949.
Braun, K. & Ahluwalia, M. S. (2017). Treatment of glioblastoma in older adults, Current Oncology Reports, 19 (12), 1-7.
Campos, J. A. D. B. et al. (2018). European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30: models factorials in patients Brazilians with cancer, Einstein (Sao Paulo), 16 (1), 1-8.
Caroli, M. et al. (2007). Temozolomide in glioblastoma: results of administration first relapse and in newly diagnosed cases. Is an alternative schedule to concomitant protocol still proposed?, Journal of Neuro-oncology, 84 (1), 71-77.
Chibbaro, S. et al. (2004). Temozolomide as a first-line agent in treating high-grade gliomas: phase II study, Journal of Neuro-oncology, 67 (1), 77-81.
Chiu, Leonard et al. (2012). Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30, Expert Review of Pharmacoeconomics & Outcomes Research, 12 (6), 831-837.
Davis, M. E. & Mulligan Stoiber, A. M. (2011). Glioblastoma multiforme : enhancing survival and quality of life, Clinical Journal of Oncology Nursing, 15 (3), 291-297.
Dinnes, J., Cave, C., Huang, S. & Milne, R. (2002). A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma, British Journal of Cancer, 86 (4), 501-505.
Domenech, M., Hernandez, A. & Balana, C. (2021). The need for geriatric scales in glioblastoma. Aging (Albany NY), 13 (14), 17959-17960.
Hamilton, D. A. (2006). Adding concomitant and adjuvant temozolomide to radiotherapy does not reduce health-related quality of life in people with glioblastoma. Cancer Treatment Reviews, 32 (6), 483-486.
Hanna, C. et al.(2020). Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis, Cochrane Database of Systematic Reviews, 3 (3), 1-133.
Karachi, A., Dastmalchi, F., Mitchel, D. A. & Rahman, M. (2018). Temozolomide for immunomodulation in the treatment of glioblastoma, Neuro-Oncology, 20 (12), 1566-1572.
Khan , R. B. et al. (2002). A phase II study of extended low-dose temozolomide in recurrent malignant gliomas, Neuro-oncology, 4 (1), 39-43.
Kocher, M. et al. (2008). Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma, Strahlentherapie und Onkologie, 184 (11), 572-579.
Kong, D. S. et al. (2010). Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma, Neuro-oncology, 12 (3), 289-296.
Lim, M., Xia, Y., Bettegowda, C. & Weller, M. (2018). Current state of immunotherapy for glioblastoma, Nature Reviews Clinical Oncology, 15 (7), 422-442.
Lombardi, G. et al. (2018). Quality of life perception, cognitive function, and psychological status in a real-world population of glioblastoma patients treated with radiotherapy and temozolomide, American Journal of Clinical Oncology, 41 (12), 1263-1271.
Lukas, R. V., Razis, E. D., Huse, J. T. (2021). An international perspective on the management of glioblastoma, Chinese Clinical Oncology, 10 (4), 107.
Malmstrom, A. et al. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomized , phase 3 trial, The Lancet Oncology, 13 (9), 916-926.
McBain, C. et al. (2021). Treatment options for progression or recurrence of glioblastoma: a network meta‐analysis, Cochrane Database of Systematic Reviews, 5 (1), 1-135.
Minniti, G. et al. (2009). Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma, Journal of Neuro-oncology, 91 (1), 95-100.
Minniti, G. et al. (2013). Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide, International Journal of Radiation Oncology, Biology, Physics, 86 (2), 285-291.
Mir, T., Pond, G. & Greenspoon, J. N. (2021). Outcomes in elderly patients with glioblastoma multiforme treated with short-course radiation alone compared to short-course radiation and concurrent and adjuvant temozolomide based on performance status and extent of resection, Current Oncology, 28 (4), 2399-2408.
Osoba, D., Brada, M, Yung, W. K. & Prado, M. (2000). Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme, Journal of Clinical Oncology, 18 (7), 1481-1491.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D. et al. (2021). The PRISMA 2020 statement : an updated guideline for reporting systematically reviews, BMJ, 372 (71), 1-9.
Paulsen, F. et al. (1999). Chemotherapy in the treatment of recurrent glioblastoma multiforme : ifosfamide versus temozolomide . Journal of Cancer Research and Clinical Oncology, 125 (7), 411-418.
Pedretti, S. et al. (2019). Hypofractionated radiation therapy versus chemotherapy with temozolomide in patients affected by RPA class V and VI glioblastoma: a randomized phase II trial, Journal of Neuro-Oncology, 143 (3), 447-455.
Perry, J. R. et al. (2017). Short-course radiation plus temozolomide in elderly patients with glioblastoma, New England Journal of Medicine, 376 (11), 1027-1037.
Pessini, L. (2009). Distanásia: até quando investir sem agredir?, Revista Bioética, 4 (1), 1-11.
Reddy, K. et al. (2013). Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide, Journal of Neuro-oncology, 114 (1), 111-116.
Reyes-Botero, G. et al. (2018). Temozolomide plus bevacizumab in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial (ATAG), The Oncologist, 23 (5), 524-e44.
Santos, C. M. C., Pimenta, C. A. M., Nobre, M. R. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana de Enfermagem, 15 (1), 508-511.
Schafer, N. et al. (2018). Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT- nonmethylated glioblastoma, Neuro-oncology, 20 (7), 975-985.
Sim, H. W., Nowak, A. K., Lwin, Z. & Khasraw, M. (2021). Management of glioblastoma: an Australian perspective, Chinese Clinical Oncology, 10 (4), 42.
Stahl, P. et al. Health-related quality of life and emotional well-being in patients with glioblastoma and their relatives, Journal of Neuro-Oncology, 149 (2), 347-356.
Taphoorn, M. J. B. et al. (2005). Health- related quality of life in patients with glioblastoma: a randomized controlled trial, The Lancet Oncology, 6 (12), 937-944.
Taphoorn, M. J. B. et al. (2015). Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide , and radiotherapy in newly diagnosed glioblastoma, Journal of Clinical Oncology, 33 (9), 2166-2175.
Taphoorn, M. J. B. et al. (2018). Influence of treatment with tumor-treating fields on health-related quality of life of patients with newly diagnosed glioblastoma: a secondary analysis of a randomized clinical trial, JAMA Oncology, 4 (4), 495-504.
Weller, J. et al. (2019). Health-related quality of life and neurocognitive functioning with lomustine – temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma ( CeTeG /NOA-09): A randomized , multicentre , open-label, phase 3 trial, The Lancet Oncology, 20 (10), 1444-1453.
Wirsching, H.G., Galanis, E. & Weller, M. (2016). Glioblastoma, Hand Clin Neuro, 134 (1), 381-397.
YIin, A. et al. (2013). Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis, Plos One, 8 (9), e74242.
Yin, A. et al. (2014). A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients, Journal of Neuro-oncology, 116 (2), 315-324.
Yung, W. K. A et al. (200). A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse, British Journal of Cancer, 83 (5), 588-593.
Zhu, J. J. et al. (2017). Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma, Journal of Neuro-oncology, 135 (3), 545-552.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2022 Thales Augusto Oliveira Dias; Dyecika Souza Couto; Edvaldo José Rodrigues Cardoso
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
Los autores que publican en esta revista concuerdan con los siguientes términos:
1) Los autores mantienen los derechos de autor y conceden a la revista el derecho de primera publicación, con el trabajo simultáneamente licenciado bajo la Licencia Creative Commons Attribution que permite el compartir el trabajo con reconocimiento de la autoría y publicación inicial en esta revista.
2) Los autores tienen autorización para asumir contratos adicionales por separado, para distribución no exclusiva de la versión del trabajo publicada en esta revista (por ejemplo, publicar en repositorio institucional o como capítulo de libro), con reconocimiento de autoría y publicación inicial en esta revista.
3) Los autores tienen permiso y son estimulados a publicar y distribuir su trabajo en línea (por ejemplo, en repositorios institucionales o en su página personal) a cualquier punto antes o durante el proceso editorial, ya que esto puede generar cambios productivos, así como aumentar el impacto y la cita del trabajo publicado.
